DOCSLIB.ORG

Symposium19 Mailer No Early Bird.Indd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Symposium19 Mailer No Early Bird.Indd Registration Information REGISTRATION FEES CREDIT DESIGNATION $450 MD, PhD (Expires Oct. 11, 2019) The Icahn School of Medicine $550 MD, PhD (Oct. 12 – Nov. 6, 2019) at Mount Sinai designates this live $150 Nurses, PAs and Allied Health Professionals activity for a maximum of 26.25 $50 Residents/Fellows AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit Mount Sinai faculty, residents, employees, voluntary commensurate with the extent of their faculty and New York Residents/Fellows are eligible for participation in the activity. scholarship, and must have a coupon code. Contact Margaret Wolf, Department of Urology for information at VERIFICATION OF ATTENDANCE [email protected] Verification of attendance will be provided to all professionals. MEETING LOCATION Mount Sinai Hospital SPECIAL NEEDS Stern Auditorium The Icahn School of Medicine at Mount Sinai is in full 1468 Madison Avenue @ 100th Street compliance with provisions of the Americans with New York, NY 10029 Disabilities Act (ADA) and is accessible for individu- als with special needs. If you would like to attend this HOTEL ACCOMMODATIONS conference and require any special needs or accom- A limited number of discounted rooms are available. modations please contact the Page and William Black Call 1-800-321-2211 and identify yourself as part of Post-Graduate School of Medicine at 212-731-7950. Mount Sinai Urology Symposium group staying at Courtyard by Marriott, Upper East Side, located at FACULTY DISCLOSURE 410 East 92nd Street, New York, NY 10128 by It is the policy of Icahn School of Medicine at Mount Monday October 7, 2019 for the special discount. Sinai to ensure objectivity, balance, independence, Or use the link: hp://bit.ly/2lZQUYM transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the ACCREDITATION planning or implementation of a sponsored activity are The Icahn School of Medicine at Mount Sinai is expected to disclose to the audience any relevant finan- accredited by the Accreditation Council for Continuing cial relationships and to assist in resolving any conflict of Medical Education (ACCME) to provide continuing interest that may arise from the relationship. Presenters medical education for physicians. must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material. November 7-9, 2019 TH INTERNATIONAL The Mount Sinai Hospital Stern Auditorium PROSTATE CANCER AND UROLOGIC ONCOLOGY SYMPOSIUM 1468 Madison Ave. @ 100th St. New York, NY 10029 In collaboration with Society of Urologic Robotic Surgeons and TH Endourological Society INTERNATIONAL November 7-9, 2019 PROSTATE CANCER AND The Mount Sinai Hospital UROLOGIC ONCOLOGY SYMPOSIUM Stern Auditorium See our Complete Agenda and Register Online: 1468 Madison Ave. @ 100th St. mountsinaiurologycme.org In collaboration with New York, NY 10029 Society of Urologic Robotic Surgeons and Endourological Society DIRECTOR: Dear Medical Colleagues: Faculty Listing Ash Tewari, MBBS, MCh, FRCS (Hon.) Professor and Chairman of the On behalf of the Department of Urology at the Icahn School of Medicine at The Mount Sinai Hospital, Sait Ozturk, PhD Mount Sinai - Department of Featured Guest Speaker Oncological Sciences Department of Urology I am thrilled to invite you to participate in the Fourth International Prostate Cancer and Urologic [email protected] Deepak Chopra, MD, FACP, is a world-renowned pioneer in integrative Ganesh Palapattu, MD, FACS Michigan Medicine Urology Oncology Symposium set for November 7-9, 2019 in New York City! medicine and personal transformation. He is the author of more than Oncology Clinic CO-DIRECTORS: eighty-six books translated into over forty-three languages, including Michael Palese, MD Mount Sinai - Department of Urology This year’s program will include over 100 experts including National and International Urologists, MD University of Miami Health System Ketan Badani, MD numerous New York Times bestsellers. Chopra’s soon-to-be-released book, Dipen Parekh, John Kellog Parsons, MD UC San Diego Health Professor of Urology and Vice Chairman of Urologic Surgeons, Urologic Oncologists and Mid-Level Providers who will provide in-depth training Metahuman: Unleashing Your Infinite Potential unravels the mysteries the Department of Urology Ramon Parsons, MD, PhD Tisch Cancer Institute at on cutting-edge medical advances and ground-breaking treatment approaches for prostate, kidney, behind everyday reality (October 1, 2109, Harmony Books). Mount Sinai [email protected] bladder, and renal cell cancers. Vipul Patel, MD, FACS University of Central Florida College of Medicine Peter Wiklund, MD, PhD Ronney Abaza, MD, FACS Ohio Health Dublin Methodist Hospital Reza Ghavamian, MD Northwell Health Dolan Family Peter Pinto, MD National Cancer Institute, National Professor of Urology SYMPOSIUM HIGHLIGHTS INCLUDE: Health Center Institutes of Health Hackensack University [email protected] Mutahar Ahmed, MD, FACS Medical Center Alvin Goh, MD Memorial Sloan Kettering Francesco Porpiglia, MD University of Turin PROSTATE DAY 1 PROSTATE DAY 2 KIDNEY & BLADDER DAY Mount Sinai - Department of Urology Olof Akre, MD, PhD Karolinska Institutet Erik Golubo, MD James Porter, MD Robotic and Laparoscopic Fellowship Natasha Kyprianou, MBBS, PhD THURSDAY 11/7/19: FRIDAY 11/8/19: SATURDAY 11/9/19: Mount Sinai - Department of Urology in Urology, Providence Health and Services Walter Artibani, MD University Hospital of Verona Neil Grafstein, MD Professor of Urology Doximity Rajveer Purohit, MD, MPH Mount Sinai -Department of • Advanced imaging in genomics for • Innovations in the management of • New progress in pre-operative Gustavo E. Ayala, MD McGovern Medical School Nate Gross, MD [email protected] Mount Sinai – Urology Ketan Badani, MD Mount Sinai - Department of Urology Mantu Gupta, MD, FRCS (Glasg.) prostate cancer castrate-sensitive prostate cancer and intra-operative imaging, 3-D Department of Urology Ganesh Raj, MD, PhD UT Southwestern Medical Center Mount Sinai –Department of Natan Bar-Chama, MD East Sujit Nair, PhD • Focus on radiomics and modelling, and ultra sound guidance Urology and Department of Obstetrics, Gynecology, and Jonathan Haas, MD NYU Winthrop Hospital Prof. Abhay Rane, OBE, MS, FRCS, FRCS Urol • Biomarkers and immunotherapy Surrey Hospital, Redhill Assistant Professor of Urology for renal tumors Reproductive Science Alexander Haese, MD University Clinic Hamburg- radiogenomics Eppendorfl Art Rastinehad, DO Mount Sinai - Department of Urology [email protected] • Update on clinical trials for Mitchell C. Benson, MD New York Presbyterian • Utility of imaging and artificial intelli- • Novel therapeutics in the Lawrence Hospital Mishop Han, MD Johns Hopkins School of Medicine Amanda Rhee, MD, MS Mount Sinai - Department of castrate-resistant treatments for Anesthesiology, Perioperative & Pain Medicine PLANNING COMMITTEE: gence in prostate cancer treatment management of metastatic renal Thomas Bessede, MD, PhD CHU Bicetre, Bicetre Stefanie Hectors, PhD Mount Sinai - Icahn School prostate cancer Paris-South University of Medicine Kenneth Rosenzweig, MD Mount Sinai - Department of Nina Bhardwaj, MD, PhD cell carcinomas: VEFG, TKIs, and Radiation Oncology • Targeted biopsy and focal therapy • Advances in multi-modal Kirsten Bibbins-Domingo, MD, PhD, MAS UCSF Ashok Hemal, MD, MCh, FACS, FRCS Wake Forest Baptist Professor of Medicine, Hematology, immunotherapy Health - Institute for Regenerative Medicine Jaspreet Sandhu, MD Memorial Sloan Kettering options for prostate cancer School of Medicine and Medical Oncology treatments for locally advanced Michael Herman, MD South Nassau Communities Douglas Scherr, MD Weill Cornell Medicine • Genomics and biomarkers for Jerry Blaivas, MD, FACS Mount Sinai - Department of [email protected] • Urinary incontinence and sexual prostate cancer Urology Hospital Howard Schi, MD Mount Sinai - Department of Urology kidney and bladder cancer Markus Hohenfellner, MD University of Heidelberg - John Sfakianos, MD Mount Sinai - Department of Urology function post-operative treatment Maurizio Buscarini, MD, PhD, MPH-MBA Universita Carlos Cordon-Cardo, MD, PhD • 3-D robotic technique for nerve Campus Bio-Medico di Roma Department of Urology Padmanee Sharma, MD, PhD The University of Texas • Advances in second line transitional Professor and Chairman of the • Improvements in imaging and tar- sparing Umberto Capitanio, MD Università Vita-Salute Simon Hughes, MBBS, MRCP, FRCR, MD (res) Guy’s and MD Anderson Cancer Center Department of Pathology cell carcinoma for bladder and San Raaele St Thomas’ NHS Foundation Trust Ryoichi Shiroki, MD, PhD Fujita Health University School geted therapy for metastatic cancer [email protected] • Status of bio tech and clinical trials kidney Giuseppe Carrieri, MD Department of Urology John Isaacs, PhD Johns Hopkins School of Medicine of Medicine • New techniques to improve in prostate cancer treatment University of Foggia Isuru Jayaratna, MD Mount Sinai – Department of Urology Keith Shoates, MBA Vista Equity Partners Matthew Galsky, MD • Improvement in surgical technique Dimple Chakravarty, PhD Mount Sinai - Department Bente Thoft Jensen, PhD Aarhus University Hospital Brian Shuch, MD UCLA Medical Center outcomes for robotic prostatectomy Professor of Medicine, Hematology, • Highlights from ASCO
Load more

Recommended publications
  • Prospectus Symp19-8-2019.Indd
    EXHIBITOR & PROMOTIONAL PARTNERSHIP PROSPECTUS TH INTERNATIONAL PROSTATE CANCER AND UROLOGIC ONCOLOGY SYMPOSIUM NOVEMBER 7-9, 2019 NEW YORK, NY MOUNTSINAIUROLOGYCME.ORG HIGHLIGHTS • Over 100 world-renowned faculty • Engaging point-counterpoint debates and • Live 3-D surgical demonstrations, including panel discussion prostate, kidney, bladder procedures • Global exposure with international web streaming of select sessions and events Welcome to the Fourth International Prostate Cancer and Urologic Oncology Symposium. EDUCATIONAL HIGHLIGHTS • Live 3-D surgery transmission covering complex urologic surgery • Comprehensive didactic lectures from the world’s leading experts in urologic oncology • Robust review of the latest advances in surgical techniques and management of prostate, kidney, and bladder cancer • Personal interaction with world-class faculty • Stimulating point-counterpoint debates on timely topics DAILY HIGHLIGHTS PROSTATE DAY 1 THUR. 11/7/19 PROSTATE DAY 2 FRI. 11/8/19 KIDNEY & BLADDER SAT. 11/9/19 • Advanced imaging in genomics • Innovations in the management of • New progress in pre-operative and for prostate cancer castrate-sensitive prostate cancer intra-operative imaging, 3-D • Biomarkers and immunotherapy modelling, and ultra sound • Focus on radiomics and guidance for renal tumors radiogenomics • Update on clinical trials for castrate-resistant treatments for • Novel therapeutics in the • Utility of imaging and artificial prostate cancer management of metastatic renal intelligence in prostate cancer cell carcinomas:
    [Show full text]
  • In the News September 30, 2016
    From: ITNDaily on behalf of Werle, Laura Subject: Mount Sinai In the News - September 30, 2016 Date: Friday, September 30, 2016 2:06:09 PM Attachments: ATT00002.txt In the News September 30, 2016 Nature – September 30 Inflammation in Patients With Cushing Disease — Claire Greenhill Circulating levels of proinflammatory cytokines are increased in patients with Cushing disease, both during active disease and after remission, according to new data published in Clinical Endocrinology. These findings demonstrate that cytokine levels are increased in patients after remission of Cushing disease, which could explain the persistent increased risk of cardiovascular-related death. The study, led by Eliza Geer, MD, a professor of endocrinology at the Icahn School of Medicine at Mount Sinai, notes that more studies are needed to determine why levels of IL-6 and IL-1β remain elevated after remission of Cushing disease. - Eliza Geer, MD, Associate Professor, Medicine, Endocrinology, Diabetes and Bone Disease, Neurosurgery, Icahn School of Medicine at Mount Sinai Learn more: http://www.nature.com/nrendo/journal/vaop/ncurrent/full/nrendo.2016.170.html WCBS – September 29 ‘Artificial Pancreas’ Expected To Make Life Easier, Healthier For Type 1 Diabetes Patients — Max Gomez A groundbreaking new device could change the lives of millions of people living with diabetes. Federal regulators just approved an artificial pancreas that can monitor and administer insulin. The key is a computer algorithm that does those calculations faster and more accurately than a patient can. “It looks at the numbers from a moment to moment basis, and it will proactively predict what is going to happen next and make clinical decisions that cannot be done at that rate.
    [Show full text]
  • In the News July 29, 2016
    From: ITNDaily on behalf of Stephanie Sherman Subject: Mount Sinai In The News - July 29, 2016 Date: Friday, July 29, 2016 11:20:39 AM Attachments: ATT00002.txt In the News July 29, 2016 WBUR News – July 28 Doctors Need A New Skill Set For This Opioid Abuse Treatment — Karen Shakerdge Braeburn Pharmaceuticals, the company behind the newly FDA-approved treatment Probuphine, is teaching doctors how to use it. Although addiction specialists welcome Probuphine, which delivers a constant dose of the drug buprenorphine over six months, at this early stage it's complicated for physicians to add it to their repertoire. Patients using Probuphine were 14 percent more likely to stay opioid-free compared to those using a daily sublingual version of buprenophine, according to a study published this month in JAMA, the Journal of the American Medical Association. So it's good to have another way to deliver medication-assisted treatment, says Richard Rosenthal, medical director of addiction psychiatry for the Mount Sinai Health System. Rosenthal was one of two principal investigators on a Probuphine clinical trial. "Everybody is waking up to the fact that we're in the midst of an opioid epidemic," says Rosenthal. "There are actually very few medications for addiction of any kind. Given the addiction treatment system in the United States, most of the treatment that's given is psychosocial. There's very little use of FDA-approved medications." - Richard N. Rosenthal. MD, Professor, Psychiatry, Mount Sinai West Learn more: http://www.wbur.org/npr/487080738/doctors-need-a-new-skill-set-for-this-opioid-abuse- treatment MD Alert – July 28 Some Non-Celiac Gluten Sensitivity Patients May Have 'Celiac Lite' Disease — Marilynn Larkin A subset of patients with non-celiac gluten sensitivity (NCGS) may actually have a form of celiac disease, researchers in Spain report.
    [Show full text]
  • PARTNERSHIP PROSPECTUS SEPTEMBER MOUNT SINAI HOSPITAL 7-9 NEW YORK, NEW YORK 2017 Second International Urologic Cancer Symposium
    EXHIBITOR AND PROMOTIONAL PARTNERSHIP PROSPECTUS SEPTEMBER MOUNT SINAI HOSPITAL 7-9 NEW YORK, NEW YORK 2017 Second International Urologic Cancer Symposium HIGHLIGHTS • Over 80 renowned global faculty • Live 3D surgical demonstrations, including prostate, kidney, bladder and reconstruction • Point-Counterpoint Debate • Annual Push Up Challenge • Gala to Raise Funds for Urologic Cancer Research TOPIC AREAS • Screening and Low Risk Disease • Localized Prostate Cancer • Biomarkers and Genomics • Advanced Prostate Cancer • Immunotherapy • Kidney Cancer • Focal Therapy • Bladder Cancer www.mountsinaiurologycme.org TABLE OFCONTENTS Invitation to Exhibit/Sponsor . 1 Department of Urology 75th Anniversary Session . 2 Screening & Low Risk Disease . 3 Focal Therapy . 4 Treatment Failure . 4 Immunotherapy & Tumor Microenvironment . 5 Radical Prostatectomy . 6 Treating Localized Disease . 7 Advanced Prostate Cancer . 8 Locally Advance Disease. 9 Quality of Life . 9 Kidney Cancer - I. 10 Kidney Cancer - II . 11 Kidney Cancer - III . 12 Bladder Cancer I . 13 Partnership Information . 14 Partnership Opportunities . 15 Exhibit Registration Form . 17 Agenda. 18 Invitation to Exhibit/Sponsor 1 Course Director Dear Industry Colleagues: Ash Tewari, MBBS, MCh On behalf of the Department of Urology at the Icahn School of Medicine at Mount Sinai Hospital in New York City, I Co –Directors would like to invite you to partner with the 2nd International Urologic Cancer Symposium being held on September On behalf of the Department of Urology at the Icahn School of Medicine at Mount Sinai Hospital in New Ketan K. Badani, MD 6-9, 2017 at the Mount Sinai School of Medicine in New York, NY. Ranked among the nation’s best for Urology York City, I would like to invite you to partner with the Second International Prostate Cancer Nina Bhardwaj, MD, PhD in the 2016-2017 "Best Hospitals" issue of U.S.
    [Show full text]
  • Curriculum Vitae [PDF]
    CURRICULUM VITAE GYAN PAREEK, M.D. Academic Address: 2 Dudley Street, Suite 174 Providence, RI 02905 Academic Telephone Number: 401-444-8570 Academic Fax Number: 401-444-6947 Mobile Number: 401-537-7763 Electronic Mail Address: [email protected] EDUCATION Undergraduate: University of Pittsburgh, Pittsburgh, PA Bachelor of Science in Neuroscience, 1991 Graduate: Roswell Park Cancer Institute, SUNY at Buffalo Buffalo, NY Master of Science, 1993 Brown University Providence, RI Master of Arts ad eundem, 2014 Harvard Medical School Boston, MA 2018-Current Harvard Certificate in Leadership Medical School: St. George’s University School of Medicine, M.D., 1998 POSTGRADUATE TRAINING Residency: Lenox Hill Hospital, New York, NY Surgery (PGY1), 7/1/1998-6/30/1999 Lenox Hill Hospital, New York, NY Surgery (PGY2), 7/1/1999-6/2000 Lenox Hill Hospital, New York, NY Urology, 7/1/2000-6/30/2004 Fellowship: Laparoscopy and Endourology, University of Wisconsin, Madison, WI Clinical Instructor, 7/1/2004-6/30/2005 1 POSTGRADUATE HONORS AND AWARDS 2004 American Urological Association Pfizer Scholar 2005 Annual Essay Contest, Second Place, “Basic Science” and “Elastographic Measurements of In-Vivo Radiofrequency Ablation Lesions of the Kidney.” Endourological Society, Amsterdam, Netherlands 2006 Urology (Gold Journal) Essay Contest, Second Place, “Shockwave Lithotripsy Success Based on Skin to Stone Distance on Computed Tomography.” American Urological Association, Atlanta, Georgia 2009 The Dean’s Excellence in Teaching Award, “Urology Clinical Elective”,
    [Show full text]
  • 2018 Star Reviewers for Urologic Oncology
    Urologic Oncology: Seminars and Original Investigations 37 (2019) 229−262 2018 Star Reviewers for Urologic Oncology While the value of any medical journal depends upon the Sabine Brookman-May, Ph.D., M.D. quality of manuscripts received, the backbone of a journal’s LMU Munich, Dept. of Urology, Munich, Germany success is created by those who review manuscripts, iden- Clint Cary, M.D., M.P.H. tify problematic issues, make critical suggestions for Urology, Indiana University School of Medicine, Indianapolis, improvement, and assist the journal’s editors in deciding on Indiana, United States a manuscript’s disposition. This is no small task, and all too Edmund Chiong, M.B.B.S., Ph.D., F.R.C.S.Ed, F.R.C.S.I, F.A.M.S often it may feel thankless. Urology, National University Health System, Singapore, Singapore By acknowledging those reviewers whom our editors Nicholas Cost, M.D. have identified as “Star Reviewers,” Urologic Oncology Department of Surgery, Division of Urology, University of seeks to underscore the outstanding work that these Colorado School of Medicine, Aurora, CO, United States reviewers have done for the Journal over the course of this Chendil Damodaran, Ph.D. past year. We also wish to identify and thank all reviewers Urology, Univiersity of Louisville, Louisville, KY, United States for their excellent work and contributions in 2018. The Alexander Glaser, M.D. April 2019 issue of Urologic Oncology will therefore con- Department of Urology, Northwestern University, Chicago, IL, tinue its tradition of recognizing its reviewers such that all United States of our 2018 Reviewers and the Editors’ “Star Reviewers” Michael Gorin, M.D.
    [Show full text]
  • In the News June 1, 2018
    From: ITNDaily Subject: Mount Sinai In The News - June 1, 2018 Date: Friday, June 01, 2018 1:51:23 PM Attachments: ATT00001.txt In the News June 1, 2018 Core77 – May 31 A Clinic And Research Lab Designed To Make The Patient Experience Pleasant and Comprehensive — Emily Engle Medical spaces need a facelift, from furnishing to digital screens to the entire patient experience. This past year, Cactus team worked closely with the Mount Sinai Health System to develop Lab100, a new type of medical environment that focuses on the different ways in which developing technologies can improve how we understand and experience medical attention and healthcare. Lab100 equips scientists with longitudinal multi-scale health data and a testbed environment to develop, validate and deploy new products and services. By closing the feedback loop between discovery science and care delivery, Lab100 creates a virtuous cycle of innovation that radically accelerates the pace at which promising ideas become clinical practice. - David Stark, MD, Assistant Professor, Health System Design and Global Health, Icahn School of Medicine at Mount Sinai, Medical Director, Institute for Next Generation Health Care Learn more: http://www.core77.com/posts/77952/A-Clinic-and-Research-Lab-Designed-to-Make-the-Patient-Experience-Pleasant-and-Comprehensible International Business Times – June 1 Mount Sinai And RenalytixAI Launch Groundbreaking Artificial Intelligence Solution For Improved Kidney Disease Management and Patient Care Mount Sinai Health System and RenalytixAI, Plc today have entered into an exclusive multi-year license and collaboration to commercialize artificial intelligence solutions to improve kidney disease detection, management and treatment for patients with diabetes and other at-risk, large-scale patient populations.
    [Show full text]
  • Curriculum Vitae
    Benjamin R. Lee, M.D. CURRICULUM VITAE Name Benjamin R. Lee, M.D. Present Position Professor and Chief of Urology with tenure University of Arizona College of Medicine Program Director, Urology Residency Present Location Division of Urology Arizona Health Sciences Center 1501 N. Campbell Ave., PO Box 245077 Tucson, AZ 85724-5077 (520) 626-6895 (Phone) (520) 626-4933 (FAX) Email Address [email protected] Education 1986-1990 Bachelor of Arts, Biological Sciences, Magna Cum Laude College of Arts and Sciences Cornell University, Ithaca, New York Senior Honors Thesis: Binding Studies of cell surface Immunoglobulin E- receptor complexes 1990-1994 M.D., Doctor of Medicine The Johns Hopkins School of Medicine Baltimore, Maryland Page 1 of 76 Benjamin R. Lee, M.D. Training / Education / Position General Surgery Internship 1994-95 The Johns Hopkins Hospital General Surgery Resident 1995-96 The Johns Hopkins Hospital Urology Resident 1996-00 The James Buchanan Brady Urological Institute The Johns Hopkins Hospital Assistant Chief Of Service (ACS) 2000-01 The Johns Hopkins Hospital Assistant Professor 2001-04 North Shore - Long Island Jewish Medical Center Albert Einstein College of Medicine Associate Professor 2004-08 North Shore - Long Island Jewish Medical Center Albert Einstein College of Medicine Director, Laparoscopy Section, Long Island Jewish Medical Center Professor (with tenure) 2008-16 Department of Urology Tulane University School of Medicine Director, Fellowship Program in Robotics, Laparoscopy & Endourology Professor 2010-16 Professor of Medicine, Section of Hematology-Oncology Tulane University School of Medicine Professor & Chief (with tenure) 2016-present Division of Urology Department of Surgery University of Arizona College of Medicine Director, GU Cancer & Disease Oriented Strategic Planning Team University of Arizona Cancer Center Program Director, Urology Residency Certification Diplomate, American Board of Urology, #13100, expires 2/28/2023 DaVinci Robotic Training Certificate 2005 Page 2 of 76 Benjamin R.
    [Show full text]
  • The Urology Residency Program of the Icahn School of Medicine at Mount Sinai
    THE UROLOGY RESIDENCY PROGRAM OF THE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI Overview The Icahn School of Medicine at Mount Sinai Urology Residency Program is an ACGME-accredited program with a training format consisting of one year of preliminary training in general surgery followed by four years of urology. Its home institution is The Mount Sinai Hospital in New York City. The program is currently approved for a complement of five residents per training year. The program curriculum assures that over the course of training, every resident receives ample experience and didactic grounding in all of the core domains and techniques of urology while acquiring the professional skills and competencies that are characteristic of excellent physicians. Each of the 19 rotations that comprise the curriculum include experience in both in-patient and out-patient treatment settings, with selected rotations offering concentrated experience in areas such as pediatric urology, urodynamics, endourology, female urology, infertility and oncology. An overarching schedule of conferences (led by faculty, fellow residents and guest lecturers), collaborative research projects and support for participation in professional organizations and special programs knit the residents’ clinical experience into the fabric of current urologic scholarship. Our home and affiliated institutions offer an immersive experience in three distinct health care delivery models: the tertiary care academic medical center, the community hospital and the municipal hospital system. Our graduates finish the program with an enviable understanding of the options that are open to them, and well equipped to pursue the urology careers of their choosing. Home and Affiliated Institutions The Mount Sinai Health System consists of seven hospital campuses, each of them a venerable New York institution, located in Manhattan, Brooklyn and Queens.
    [Show full text]
  • 2017 Annual Meeting
    PRELIMINARY PROGRAM Register at cns.org/2017 Advance Registration Deadline: September 7, 2017 2017 CNS2017 ANNUAL MEETING PRELIMINARY PROGRAM TION CELE ORMA BRAT NSF ION TRA CONGRESS OF NEUROLOGICAL SURGEONS 2017 ANNUAL MEETING BOSTON, MASSACHUSETTS # OCTOBER 7–11, 2017 PRESIDENT’S MESSAGE Change is inevitable. In the moments that pass as you read this, mountains erode, plants and animals adapt, and stars dim—all in imperceptibly slow motion. In a similar way, our profession changes. As our knowledge grows exponentially and technology accelerates, we must also adapt and transform into what is possible. Essentially, this has been the core of every CNS Annual Meeting for the past 67 years—to assess our reality, anticipate a better future, point our collective energies in the direction of that future, and prepare for the change we must create. Simultaneously, it is also important to note all that we have accomplished. Neurosurgery can proudly say that what was lethal only a few generations ago, is now survivable. Our ongoing achievements deserve our admiration and are cause for celebration. This paradox between all we have done and all that we have left to do is what drives us to become better. It is also the driving concept behind this year’s CNS Annual Meeting theme Transformation and Celebration. Within this Preliminary Program, you will see dozens of educational programs and sessions containing both today’s state-of-the-art neurosurgery and insight into how neurosurgery is changing. You will find some courses that look familiar and some that are completely new. Some formats that were once didactic and lecture-driven have been transformed into interactive and hands-on.
    [Show full text]
  • Symposium 2018 V2-For Emailing.Indd
    December 13-15, 2018 The Mount Sinai Hospital 1 Gustave L. Levy Place New York, NY In collaboration with Society of Urologic Robotic Surgeons and Endourological Society DIRECTOR: Dear Medical Colleagues: Ash Tewari, MBBS, MCH Professor and Chairman of the Department of Urology On behalf of the Department of Urology at the Icahn School of Medicine at Department of Urology Mount Sinai in New York City, I am thrilled to invite you to participate in the [email protected] Third International Prostate Cancer and Urologic Oncology Symposium set for CO-DIRECTOR: December 13-15, 2018 in New York! This year’s program is our most innovative yet, Ketan Badani, MD complete with over 100 world-renowned experts who will provide in-depth Professor of Urology and Vice Chairman of the training on cutting-edge medical advances and ground-breaking treatment Department of Urology Department of Urology approaches for prostate, kidney, bladder, and renal cell cancers. [email protected] PLANNING COMMITTEE: Nina Bhardwaj, MD, PhD SYMPOSIUM TOPICS Professor of Medicine, Hematology, n and Medical Oncology Epidemiology and Early Diagnosis of Prostate Cancer Department of Medicine, Hematology, and n Staging, Imaging, and Genomics Medical Oncology n [email protected] Management of Very Low Risk and Low Risk Prostate Cancer n Focal Therapy Carlos Cordon-Cardo, MD, PhD n Professor and Chairman of the Department of Surgical Treatment of Intermediate Risk Prostate Cancer Pathology n Sexual Health Following Prostatectomy Department of Pathology [email protected]
    [Show full text]
  • International Prostate Cancer and Urologic Oncology Symposium
    EXHIBITOR & PROMOTIONAL PARTNERSHIP PROSPECTUS 2018 RD 3 INTERNATIONAL PROSTATE CANCER AND UROLOGIC ONCOLOGY SYMPOSIUM DECEMBER 13-15, 2018 NEW YORK, NY MOUNTSINAIUROLOGYCME.ORG HIGHLIGHTS • Over 100 world-renowned faculty • Engaging point-counterpoint debates and • Live 3D surgical demonstrations, including panel discussion prostate, kidney, bladder procedures • Global exposure with international web streaming of select sessions and events TOPIC AREAS • Epidemiology and Early Diagnosis of Prostate Cancer • Staging, Imaging, and Genomics • Management of Very Low Risk and Low Risk Prostate Cancer • Focal Therapy • Surgical Treatment of Intermediate Risk Prostate Cancer • Sexual Health Following Prostatectomy • Radical Prostatectomy • Immunotherapy and Tumor Microenvironment • Upper Tract Disease • Partial Nephrectomy • Kidney Cancer • Bladder Cancer • PARP Inhibitors in Prostate Cancer DECEMBER 13 – 15, 2018 NEW YORK, NY EXHIBITOR & PROMOTIONAL PARTNERSHIP PROSPECTUS DIRECTOR: ASH TEWARI, MBBS MCH Professor and Chairman of the Department INVITATION of Urology Department of Urology TO EXHIBIT/SPONSOR [email protected] CO-DIRECTOR: Dear Industry Colleagues: KETAN BADANI MD Professor of Urology and Vice Chairman of the Department of Urology On behalf of the Department of Urology at the Icahn School of Medicine at Department of Urology Mount Sinai in New York City, I am thrilled to invite you to participate in the Third [email protected] International Prostate Cancer and Urologic Oncology Symposium set for December 13-15, 2018 in New York! This year’s program is our most innovative yet, complete PLANNING COMMITTEE: with over 100 world-renowned experts who will provide in-depth training on cutting- NINA BHARDWAJ MD, PhD edge medical advances and ground-breaking treatment approaches for prostate, Professor of Medicine, Hematology, kidney, bladder, and renal cell cancers.
    [Show full text]